Optovue Introduces AngioVue OCTA in Glaucoma

June 10, 2015

Robert N. Weinreb, MD Presents at World Glaucoma Congress

FREMONT, CA – JUNE 10, 2015 – Optovue, a pioneer in optical coherence tomography angiography (OCTA) and leader in commercialization of the technology, announced that it has expanded the application of its OCT Angiography technology into glaucoma. After a successful introduction of the revolutionary AngioVue Imaging System to retina last year, Optovue has worked to develop clinical applications in glaucoma as well.

The use of the AngioVue Imaging System in glaucoma was introduced at a highly successful symposium at the 6th World Glaucoma Congress in Hong Kong. The Optovue-hosted event featured presentations on the clinical applications of OCTA in glaucoma research using the company's AngioVueTM OCTA system.

Robert N. Weinreb, M.D., Chairman and Distinguished Professor of Ophthalmology at the University of California, San Diego, Director of the Shiley Eye Institute and Director of the Hamilton Glaucoma Center presented his early work with the AngioVue Imaging System in glaucoma research to a large crowd in Hong Kong. “OCT Angiography allows easier and more detailed visualization of the Radial Peripapillary Capillary Layer than is possible with Fluorescein Angiography, the current gold standard in vascular imaging,” said Dr. Weinreb, going on to state that this new method will open doors in glaucoma research.

About AngioVue™ Imaging System*
The AngioVue Imaging System is a non-invasive, dyeless technique for visualizing the presence of ocular flow in the vessels. AngioVue allows clinicians to assess microvasculature and perfusion in ocular diseases with unprecedented detail. Unlike other imaging methods which utilize contrast agents, AngioVue allows visualization of microvasculature within specific layers of the retina, without the blurring or obscuring effects of staining or pooling.

The unique combination of two proprietary technologies enables AngioVue to integrate easily with clinical workflow. Patent pending Split Spectrum Amplitude Decorrelation Angiography (SSADA) enables high quality vascular imaging with a higher signal to noise ratio ¬– reducing scan time to less than three seconds – while patent pending Motion Correction Technology (MCT™) minimizes motion artifacts to further improve image quality.

More than 300 commercial AngioVue systems have been installed outside of the U.S. since Optovue first introduced the technology and device seven months ago, indicating that AngioVue and OCT-Angiography have expanded from clinical research into daily clinical practice.

*The AngioVueTM OCTA Imaging System is not currently available for sale in the US

About Optovue
Optovue, Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities. Incorporated in December 2003, Optovue was founded to develop the next generation ophthalmic diagnostic instrument based on ultra-high speed optical coherence tomography (OCT) technology. Optovue has since achieved widespread market success through a combination of unique product design, rapid innovation of its technology and a commitment to customer satisfaction. For more information, visit www.optovue.com.

Contact:
Christina Kirby
Marketing Director
christina_kirby@optovue.com
510-857-9704

PN 300-50540 Rev. A

Optovue Highlights World's First OCTA Metrics at AAO 2018

Optovue Introduces First Software-Assisted OCT Device to US Market